Welcome to our dedicated page for Olink Holding Ab (Publ) news (Ticker: OLK), a resource for investors and traders seeking the latest updates and insights on Olink Holding Ab (Publ) stock.
Olink Holding AB (OLK) drives innovation in proteomics through advanced biomarker discovery platforms that accelerate clinical research. This news hub provides investors and researchers with timely updates on scientific breakthroughs, financial developments, and strategic initiatives shaping the future of precision medicine.
Access authoritative reports on OLK's quarterly earnings, technology partnerships with leading biopharma companies, regulatory milestones for diagnostic tools, and expansions of its global research network. Our curated collection ensures transparent access to primary source materials and verified corporate announcements.
Key focus areas include platform enhancements for protein analysis, collaborations with academic medical centers, and clinical validation studies supporting therapeutic development. Users benefit from organized updates across OLK business units without promotional bias or speculative commentary.
Bookmark this page for streamlined tracking of OLK's contributions to next-generation healthcare solutions. Check regularly for essential updates that inform investment decisions and research strategies in the evolving proteomics sector.
Olink Holding AB (Nasdaq: OLK) announced the launch of CORAL, a collaborative initiative aimed at identifying novel protein biomarkers for neurological diseases using its Proteomics platform. This effort includes studies on blood and cerebrospinal fluid (CSF) to enhance diagnostics and treatment response evaluation. CORAL’s focus encompasses various neurological conditions, including Alzheimer’s and Parkinson’s diseases. Olink’s innovative Proximity Extension Assay technology will facilitate this research, aiming to translate findings into clinically useful biomarker tests, thereby improving patient outcomes.
Olink Holding AB (Nasdaq: OLK) announced an expansion of the UK Biobank Pharma Proteomics Project (UKB-PPP), involving a study of 53,000 participants. The project will transition from the Olink Explore 1536 to the Olink Explore 3072 platform, increasing the available assays from 1,500 to nearly 3,000. This expansion, now supported by twelve biopharmaceutical companies, aims to enhance understanding of disease biology and drug development. CEO Jon Heimer expressed confidence in their Proximity Extension Assay technology, emphasizing its role in delivering actionable insights.
Olink Holding (Nasdaq: OLK) announced a public offering of 7,500,000 American Depositary Shares (ADSs) at $31.00 each, to be sold by certain shareholders. An additional 1,125,000 ADSs may be purchased by underwriters within 30 days. The offering is expected to close around July 19, 2021, pending customary conditions. The shareholders will retain all proceeds from the offering, while Olink will not receive any funds. Goldman Sachs and Morgan Stanley are leading the offering process.
Olink Holding AB (Nasdaq: OLK) has announced a collaboration with deCODE genetics to utilize the Olink Explore 3072 platform, which includes approximately 3,000 protein assays. This partnership positions deCODE as an early adopter, aiming to optimize high-throughput proteomics for healthcare advancements. Olink plans to make this platform widely available in Q4 2021. CEO Jon Heimer emphasized the importance of their proprietary PEA technology and the breadth of applications it enables in clinical trials and diagnostics.
Olink Holding AB (Nasdaq: OLK) announced preliminary revenue of $17.3 to $17.7 million for Q2 2021, a significant increase compared to $7.9 million in Q2 2020. However, the expected net loss ranges from $(10.4) million to $(10.8) million, up from $(2.0) million in the same period last year. These results are subject to adjustment upon quarter-end closing. Olink plans to report full Q2 results on August 11, 2021, with a conference call scheduled for 8:00 a.m. E.T.
Olink Holding AB (Nasdaq: OLK) has announced a public offering of 7,000,000 American Depositary Shares (ADSs) by certain selling shareholders, with an option for underwriters to purchase an additional 1,050,000 ADSs. Olink will not receive any proceeds from this offering, which is subject to market conditions. Goldman Sachs and Morgan Stanley are leading the offering, and Olink's registration statement is pending effectiveness with the SEC. This offering emphasizes Olink's role in the proteomics field aimed at improving patient health outcomes.
Olink Holding AB (Nasdaq: OLK) has launched Olink Explore 3072, enhancing its library with ~3000 validated assays. This product significantly extends its protein biomarker discovery capabilities, using Proximity Extension Assay (PEA) technology with next-generation sequencing on Illumina platforms. Customers can process over 4600 samples weekly, measuring almost 3000 proteins. Orders for the kits start now, with deliveries expected in Q4 2021. Olink aims to democratize access to proteomics, providing vital resources for research into various diseases.
Olink Holding AB (Nasdaq: OLK) announced the launch of the SCALLOP consortium's new clinical trial arm, aimed at enhancing proteomic profiling in clinical research. The initiative seeks to improve statistical power by increasing the reference sample size, thus aiding the detection of protein level changes during trials. This framework will benefit participants with access to Olink's reference data and a dedicated project coordinator, all while maintaining GDPR compliance. The consortium now includes 28 research institutions covering nearly 65,000 patients.
Olink Holding AB (Nasdaq: OLK) has launched the Olink Signature Q100, an affordable benchtop system aimed at enhancing access to high-quality proteomics data for researchers. The system allows simultaneous measurement of up to 92 proteins using just one microliter of plasma or serum. This new product complements the existing Olink Explore platform and is designed specifically for the Olink Target and Focus biomarker panels. Deliveries are expected in Q4 2021, following pre-orders starting June 2, 2021.
Olink Holding AB (Nasdaq: OLK) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 8:50 a.m. ET. CEO Jon Heimer and CFO Oskar Hjelm will engage in a virtual fireside chat during the event. A live and archived webcast will be accessible on the Olink investors' website for interested parties.
Founded in 2016 and based in Uppsala, Sweden, Olink focuses on advancing proteomics to enhance healthcare through innovative solutions utilized by biopharmaceutical firms and academic institutions.
